ANN ARBOR, Mich. — A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed a novel artificial intelligence tool that not only identifies disease-causing genetic mutations but also predicts the type of ...

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: It depends on ...

– Scientists at the Icahn School of Medicine at Mount Sinai have developed a new artificial intelligence tool called V2P (Variant to Phenotype) that identifies not only disease-causing genetic ...